About: http://data.cimple.eu/news-article/f1a4122794a49748000017f1d69e738da5676f2f4e711b4e0b4f19d9

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/f1a4122794a49748000017f1d69e738da5676f2f4e711b4e0b4f19d9 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Johnson & Johnson's single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced Friday, following results from a phase 3 trial of almost 44,000 people across many countries. The figure however was as high as 72 percent in the United States but went down to 57 percent in South Africa, where a more transmissible variant is dominant. The company added that the vaccine was 85 percent effective in preventing severe Covid-19 across all geographical regions. "We're proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere," the company's CEO Alex Gorsky said. The company is quickly expected to apply for a US emergency authorization, and could therefore soon be the third vaccine available in the world's hardest-hit country. The Pfizer and Moderna vaccines were the first to be authorized in the US, and both have efficacies of around 95 percent. But the comparisons are not considered like-for-like, because those trials reported results before newer, more transmissible mutations of the virus became dominant in some parts of the world. These variants, such as B.1.135 in South Africa and P.1 in Brazil, elude some of the blocking action of antibodies triggered from vaccines made against the common strain of the coronavirus. The fact that the J&J vaccine requires only one shot, and can be stored for up to three months at 2-8 degrees Celsius, give it major logistical advantages over the Pfizer and Moderna vaccines. These two are based on mRNA technology and require deep freezing. ia/dw
schema:headline	J&J Covid vaccine moderately effective, less against S. Africa variant
schema:mentions	Global health Deutsche Welle Johnson & Johnson Antibody Ia (cuneiform) Africa Messenger RNA South Africa Chief executive officer Virus Pfizer Coronavirus disease Brazil Vaccine United States Coronavirus Coronavirus disease 2019 Alex Gorsky Single-shot
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-01-29 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	75 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software